Table 1.
Compounds treating mitochondrial dysfunction/oxidative stress currently in clinical trials.
| Compound | Molecular/Cellular Target | Clinical Trial Stage | Registration Number | References |
|---|---|---|---|---|
| ASP0367 | PPARδ | Phase 1b | NCT04184882 | [130,131] |
| (-)-epicatechin | Energy metabolism | Phase 1 | NCT04386304 | [132,133,134] |
| resveratrol | SIRT1-PGC-1α axis/oxidative stress | Phase 2a | UMIN000014836 | [135,136,137,138,139] |
| metformin | AMPK/respiratory chain complex I | Phase 2 Phase 3 |
NCT02018731 NCT01995032 |
[140,141,142] |
| l-citrulline | NO system | Phase 2 Phase 3 |
NCT02018731 NCT01995032 |
[140,141,142] |
| givinostat | HDAC/mitochondrial biogenesis program | Phase 2 Phase 3 |
NCT01761292 NCT02851797 |
[29,42] |